Thursday, November 26, 2015

FDA advisory panel endorses pill to prevent HIV infection

An FDA panel voted to endorse Truvada, a pill that is supposed to prevent HIV infection.

FDA advisory panel endorses pill to prevent HIV infection


A U.S. Food and Drug Administration advisory panel voted Thursday to endorse a pill that is supposed to prevent HIV infection.

Truvada is a once-a-day pill meant to ward off the virus for higher-risk patients, which includes heterosexual partners with one partner being HIV positive and gay and bisexual men.

Gilead Sciences Inc., is based in Foster City, Calif. The company makes Truvada and has sold it since 2004 as a treatment for HIV/AIDS. This request was to expand the label to include people who don't yet have the virus.

The FDA does not have to follow advisory panel decisions, but it usually does.

Many in the AIDS community backed the proposal because they have searched for a prevention drug. Others fretted that people would not diligently take the pill as prescribed and others were worried that it would detract from the use of condoms, which has been proven to to stop the spread of the virus.

The Associated Press reported that panel member Dr. Tom Giordano of Baylor College of Medicine voted in favor of approval.

"The trouble is adherence, but I don't think it's our charge to judge whether people will take the medicine," Giordano said, according to AP. "I think our charge is to judge whether it works when it's taken and whether the risks outweigh the benefits."



Inquirer Staff Writer
We encourage respectful comments but reserve the right to delete anything that doesn't contribute to an engaging dialogue.
Help us moderate this thread by flagging comments that violate our guidelines.

Comment policy: comments are intended to be civil, friendly conversations. Please treat other participants with respect and in a way that you would want to be treated. You are responsible for what you say. And please, stay on topic. If you see an objectionable post, please report it to us using the "Report Abuse" option.

Please note that comments are monitored by staff. We reserve the right at all times to remove any information or materials that are unlawful, threatening, abusive, libelous, defamatory, obscene, vulgar, pornographic, profane, indecent or otherwise objectionable. Personal attacks, especially on other participants, are not permitted. We reserve the right to permanently block any user who violates these terms and conditions.

Additionally comments that are long, have multiple paragraph breaks, include code, or include hyperlinks may not be posted.

Read 0 comments
comments powered by Disqus
About this blog
David Sell blogs about the region's pharmaceutical industry. Follow him on Facebook.

Portions of this blog may also be found in the Inquirer's Sunday Health Section.

Reach David at or 215-854-4506.

David Sell Inquirer Staff Writer
Also on
letter icon Newsletter